益肾清利、和络汇浊法抗肾脏纤维化的机制与治疗2-3期慢性肾脏病的临床疗效评价
|
摘要
目的:肾脏纤维化是慢性肾脏病发展为慢性肾衰竭的主要原因,慢性肾脏病在发展为慢性肾衰竭的过程中有一个共同的病理学特点:从纤维化到硬化。肾脏纤维化的病理特征主要表现为细胞外基质积聚,肾小球正常结构消失,肾脏功能逐渐丧失直至废用。导致这种病理变化并最终出现肾功能下降的因素有以下几个方面:蛋白尿、血脂代谢异常、凝血和血液流变学异常、足细胞损害、肾脏组织及细胞因子的表达和代谢异常。首先,实验研究以阿霉素肾病大鼠作为实验对象,通过对实验动物的蛋白尿、血液生化、血液流变学、足细胞标志蛋白和肾脏组织及细胞因子的动态检测,探讨益肾清利、和络泄浊疗法治疗阿霉素肾病大鼠的机制及疗效。临床研究对已经接受完善降压、纠酸、调脂、改善水电平衡等基础治疗的慢性肾脏病2-3期“肾虚湿瘀证”的患者开展临床研究,以仅接受基础治疗的慢性肾脏病2-3患者作为对照组,评价以“益肾清利、和络泄浊法”为主的中医疗法的疗效,为进一步深入探讨中医辨证治疗在慢性肾脏病临床治疗中的作用寻求依据。
方法:实验研究,参考相关文献,应用阿霉素对SD大鼠尾静脉进行一次性注射,造成大鼠肾脏产生类似人类慢性肾炎的病理学改变。按照实验设计将大鼠随机分为空白对照组、模型组、阴性对照组、中药治疗组、西药治疗组、中药+西药治疗组。动态留取大鼠实验开始后24小时小便标本,测定尿蛋白定量和尿N-酰—β—D—葡萄糖酐酶(NAG)酶;不同时间点测定血清肌酐(Scr)、尿素氮(BUN)、白蛋白(ALB)、甘油三脂(TG)、胆固醇(CHO)水平。造模后第8周末处死大鼠,取出肾脏组织分别处理,然后应用光学显微镜观察肾脏组织病理学形态变化,应用免疫组织化学法检测组织纤维化相关细胞因子如纤维连接蛋白(FN)、基质金属蛋白酶(MMP-9)和胶原Ⅳ(CoⅣ)的含量,应用分子生物学研究方法以及图象分析技术,分析各组大鼠肾脏组织中TIMP—1、TGF-β1、MMP-9和Nephrin的表达水平。临床研究,按照美国NKF-K/DOGI工作组制定的《慢性肾脏病及透析的临床实践指南Ⅱ》中的诊断标准和中国国家食品和药品监督管理局制定的《中药新药临床指导原则(慢性肾衰竭)》中的诊断标准和治疗原则,对多种影响肾脏功能的因素进行临床监测。在控制血压、纠正水电解质紊乱等治疗的基础上,应用以益肾清利、和络泄浊法为原则辨证论治的中药方剂,对2—3期慢性肾脏病患者的相关实验室检查项目、中医症候积分动态观察,对比不同疗法的临床疗效。
结果:实验研究,阿霉素肾病大鼠的中药治疗组尿蛋白含量和尿NAG酶与阿霉素肾病大鼠模型组和西药治疗组比较减轻明显。实验结果还提示中药配合西药可以调节脂代谢,降低胆固醇水平和改善血液流变学情况,使血浆粘度下降。肾脏的病理组织学观察发现模型组的肾小球、细胞外基质和肾小管间质病变明显。中药治疗组、西药治疗组和中药+西药治疗组与模型组比较可见上述改变出现不同程度的减轻。免疫组织化学中应用光密度积分定量检测肾脏组织的组织纤维化相关因子如FN、MMP-9和CoⅣ的含量情况。通过SPSS统计软件分析表明,各治疗组的表达量与模型组之间有明显差别,提示各组治疗药物可以抑制阿霉素肾病大鼠肾脏细胞外基质增生相关的细胞因子的过度表达。我们应用逆转录聚合酶链式反应(RT-PCR)的方法检测各组大鼠肾脏组织的TIMP—1、TGF-β_1、MMP-9和Nephrin指标的RNA表达情况。各组治疗药物(不含阴性对照组)可以减轻阿霉素肾病大鼠纤维化正相关因子TIMP—1和TGF-β_1的表达。中药+西药治疗组疗效明显优于其他各组,差异有显著性(P＜0.05)。肾脏纤维化负相关因子MMP-9和足细胞相关蛋白Nephrin的RNA表达情况提示各组治疗药物(不含阴性对照组)可以保护阿霉素肾病大鼠肾脏足细胞并提高纤维化负相关因子MMP-9的表达量,中药+西药治疗组疗效明显优于其他各治疗组,差异有显著性。
临床研究病例来源于江苏省中医院和苏州大学附属第一医院的门诊和住院患者,共纳入2—3期慢性肾脏病患者90例,其中男性58例,女性32例。收集患者相关的临床数据资料,应用SPSS15.0统计软件分析。统计分析结果提示,以益肾清利、和络泄浊为治疗原则的中药方剂与西药基础治疗相配合的中西药治疗组与单纯西药基础治疗组进行比较。结合相关临床疗效指标提示中西药治疗组相比单纯西药治疗组,可以降低患者肾脏功能的下降速度,改善患者的症候,提高患者临床疗效和依从性。
结论:“益肾清利、和络泄浊法”的中药方剂,可以减少阿霉素肾病大鼠的蛋白尿、降低尿液的NAG酶、减轻肾脏组织细胞外基质合成、抑制TIMP、TGF-β1的表达、提高抗组织纤维化因子MMP-9和足细胞标志蛋白(nephrin)的表达。中药方剂和贝那普利合用可以起到协同作用,提高抗肾脏纤维化的治疗效果。临床应用发现中药方剂具有补益脾肾、益气养血等作用。临床研究统计数据表明配合了西药的基础治疗,可以更有效地减少患者蛋白尿、保护患者肾功能,降低肾功能的下降速度。
Objective:Fibrotic kidney is a common characteristic during the course from chronic kidney disease to chronic renal failure(CRF).The pathological feature of fibrotic kidney is progressing extracellular matrix accumulation.The result is the loss of normal structure of the glomerulus,the destroy of nephron and the deprivation of renal function.The treatment of tonifying kidney & regulating and dispersing muddy(TKRDM) is a kind of means which is set up by professor sun wei.The study includes two parts.First we establish an animal model of renal sclerosis by adriamycin(ADM).Then we use the TKRDM to treat the animal and observe the change of biochemical indicator,the change of histopathology,the change of ECM,the change of cytokine and the marker of cell.Second,we use the TKRDM to treat the patient by 2-3 stage chronic renal disease.
Approaches:Research study:1.We did once-intravenous injections to establish an animal model for diffusion mesangioproliferation following with focal segmental glomerulosclerosis.The rats were randomly divided into sham group,adriamycin nepropathy(AN),TKRDM group, benazepril group,TKRDM and benazepril group.Urinary protein excretion,serum urea nitrogen,serum creatinine,albumin,serum cholesterol and triglyceride were be detected by automatic biochemistry meter.We detected the cytokine and the marker of cell,which includes collagenⅣ(CoⅣ),fibronectin(FN),the transforming growth factor-β_1,by the means of immunohistochemistry and molecular biology.2.We would analyse the date by the statistics software.
Clinic study:1.We set up the diagnostic criteria and therapeutic principle according to Clinical practice guide for the chronic renal disease and dialysis which was compiled by American NKF-K/DOGI group and Clinical practice guide to the new medicine of TCM which was compiled by the National Food and Medicine Administration Bureau.2.We used the TKRDM to treat the patient by 2-3 stage chronic renal failure and concluded the Urinary protein excretion,the serum urea nitrogen and calculated the date of renal function.3.We analysed the date by the SPSS15.0 statistics software.
Result:TKRDM and benazepril have significantly difference in proteinuria extract and urinary NAG enzyme,the serum total cholesterol was significantly distinguished by statistic means. TKRDM can improve the circulating of the blood but the benazepril doesn't have the effect.We can get a significant conclusion by statistic ways.We observed the tissue of the kidney by the way of pathohistology.We could find that the intercapillary cells and the ECM had obviously proliferation in the group of the AN.There were many foam cells in glomerulus of kidney.The cell of the renal tubule had vacuolar degeneration,analosis and cellular necrosis.There were also many protein cast and RBC cast in the nephric tubule.TKRDM group,benazepril group, TKRDM and benazepril group had different degree lessens for the index from the pathohistology. We found the group of the TKRDM and benazepril had the best conclusion by statistic way.We tested the FN,TGF-β1,MMP-9 and Col-Ⅳwhich were the compositions correlating with the fibrotic tissue by immunohistochemistry.Then we analyzed the compositions in the payhofigure by the semiquantitative analysis.TKRDM group,benazepril group,TKRDM and benazepril group could restrain the overexpression of the cytokine for the AN.In the mechanism of molecular biology,we used the ways of reverse transcription polymerase chain reaction(RT-PCR).We analyzed the cytokines which included TIMP,TGF-β1,Nephrin.All of the cytokines had a high of the date in the group of AN.The others of experimental groups had a relative lower dates.
We used the TKRDM to treat patients.Then we write down the symptoms and the renal function every month.All the symptoms,were selected from Clinical practice guide for the chronic renal disease and dialysis and Clinical practice guide to the new medicine of TCM,which correlate with the chronic renal disease.We analyzed all of the date which come from the symptoms and the renal function by spss15.0 statistic software.
Conclusion:From the dates and the analyzing of the experiments,we could get the results. First TKRDM can decrease the proteinuria and protect the function of the renal tubular for AN in rats.Second TKRDM can reduce the proliferation of ECM at different levels for AN in rats.If we use the TKRDM and benazepril,the effects of the therapeutic action will be better than use any other one of them.
For the chronic study,TKRDM can tonify spleen and kidney,benefit vital energy and smooth the blood vessel.TKRDM can also elevate the function of the entrails.The experiment hints the two points by analyzing the date of statistic results.First the TKRDM can decrease proteinuria extract and urinary NAG enzyme.Second the TKRDM can delay the aggravate speed of the renal function.
方法:实验研究,参考相关文献,应用阿霉素对SD大鼠尾静脉进行一次性注射,造成大鼠肾脏产生类似人类慢性肾炎的病理学改变。按照实验设计将大鼠随机分为空白对照组、模型组、阴性对照组、中药治疗组、西药治疗组、中药+西药治疗组。动态留取大鼠实验开始后24小时小便标本,测定尿蛋白定量和尿N-酰—β—D—葡萄糖酐酶(NAG)酶;不同时间点测定血清肌酐(Scr)、尿素氮(BUN)、白蛋白(ALB)、甘油三脂(TG)、胆固醇(CHO)水平。造模后第8周末处死大鼠,取出肾脏组织分别处理,然后应用光学显微镜观察肾脏组织病理学形态变化,应用免疫组织化学法检测组织纤维化相关细胞因子如纤维连接蛋白(FN)、基质金属蛋白酶(MMP-9)和胶原Ⅳ(CoⅣ)的含量,应用分子生物学研究方法以及图象分析技术,分析各组大鼠肾脏组织中TIMP—1、TGF-β1、MMP-9和Nephrin的表达水平。临床研究,按照美国NKF-K/DOGI工作组制定的《慢性肾脏病及透析的临床实践指南Ⅱ》中的诊断标准和中国国家食品和药品监督管理局制定的《中药新药临床指导原则(慢性肾衰竭)》中的诊断标准和治疗原则,对多种影响肾脏功能的因素进行临床监测。在控制血压、纠正水电解质紊乱等治疗的基础上,应用以益肾清利、和络泄浊法为原则辨证论治的中药方剂,对2—3期慢性肾脏病患者的相关实验室检查项目、中医症候积分动态观察,对比不同疗法的临床疗效。
结果:实验研究,阿霉素肾病大鼠的中药治疗组尿蛋白含量和尿NAG酶与阿霉素肾病大鼠模型组和西药治疗组比较减轻明显。实验结果还提示中药配合西药可以调节脂代谢,降低胆固醇水平和改善血液流变学情况,使血浆粘度下降。肾脏的病理组织学观察发现模型组的肾小球、细胞外基质和肾小管间质病变明显。中药治疗组、西药治疗组和中药+西药治疗组与模型组比较可见上述改变出现不同程度的减轻。免疫组织化学中应用光密度积分定量检测肾脏组织的组织纤维化相关因子如FN、MMP-9和CoⅣ的含量情况。通过SPSS统计软件分析表明,各治疗组的表达量与模型组之间有明显差别,提示各组治疗药物可以抑制阿霉素肾病大鼠肾脏细胞外基质增生相关的细胞因子的过度表达。我们应用逆转录聚合酶链式反应(RT-PCR)的方法检测各组大鼠肾脏组织的TIMP—1、TGF-β_1、MMP-9和Nephrin指标的RNA表达情况。各组治疗药物(不含阴性对照组)可以减轻阿霉素肾病大鼠纤维化正相关因子TIMP—1和TGF-β_1的表达。中药+西药治疗组疗效明显优于其他各组,差异有显著性(P＜0.05)。肾脏纤维化负相关因子MMP-9和足细胞相关蛋白Nephrin的RNA表达情况提示各组治疗药物(不含阴性对照组)可以保护阿霉素肾病大鼠肾脏足细胞并提高纤维化负相关因子MMP-9的表达量,中药+西药治疗组疗效明显优于其他各治疗组,差异有显著性。
临床研究病例来源于江苏省中医院和苏州大学附属第一医院的门诊和住院患者,共纳入2—3期慢性肾脏病患者90例,其中男性58例,女性32例。收集患者相关的临床数据资料,应用SPSS15.0统计软件分析。统计分析结果提示,以益肾清利、和络泄浊为治疗原则的中药方剂与西药基础治疗相配合的中西药治疗组与单纯西药基础治疗组进行比较。结合相关临床疗效指标提示中西药治疗组相比单纯西药治疗组,可以降低患者肾脏功能的下降速度,改善患者的症候,提高患者临床疗效和依从性。
结论:“益肾清利、和络泄浊法”的中药方剂,可以减少阿霉素肾病大鼠的蛋白尿、降低尿液的NAG酶、减轻肾脏组织细胞外基质合成、抑制TIMP、TGF-β1的表达、提高抗组织纤维化因子MMP-9和足细胞标志蛋白(nephrin)的表达。中药方剂和贝那普利合用可以起到协同作用,提高抗肾脏纤维化的治疗效果。临床应用发现中药方剂具有补益脾肾、益气养血等作用。临床研究统计数据表明配合了西药的基础治疗,可以更有效地减少患者蛋白尿、保护患者肾功能,降低肾功能的下降速度。
Objective:Fibrotic kidney is a common characteristic during the course from chronic kidney disease to chronic renal failure(CRF).The pathological feature of fibrotic kidney is progressing extracellular matrix accumulation.The result is the loss of normal structure of the glomerulus,the destroy of nephron and the deprivation of renal function.The treatment of tonifying kidney & regulating and dispersing muddy(TKRDM) is a kind of means which is set up by professor sun wei.The study includes two parts.First we establish an animal model of renal sclerosis by adriamycin(ADM).Then we use the TKRDM to treat the animal and observe the change of biochemical indicator,the change of histopathology,the change of ECM,the change of cytokine and the marker of cell.Second,we use the TKRDM to treat the patient by 2-3 stage chronic renal disease.
Approaches:Research study:1.We did once-intravenous injections to establish an animal model for diffusion mesangioproliferation following with focal segmental glomerulosclerosis.The rats were randomly divided into sham group,adriamycin nepropathy(AN),TKRDM group, benazepril group,TKRDM and benazepril group.Urinary protein excretion,serum urea nitrogen,serum creatinine,albumin,serum cholesterol and triglyceride were be detected by automatic biochemistry meter.We detected the cytokine and the marker of cell,which includes collagenⅣ(CoⅣ),fibronectin(FN),the transforming growth factor-β_1,by the means of immunohistochemistry and molecular biology.2.We would analyse the date by the statistics software.
Clinic study:1.We set up the diagnostic criteria and therapeutic principle according to Clinical practice guide for the chronic renal disease and dialysis which was compiled by American NKF-K/DOGI group and Clinical practice guide to the new medicine of TCM which was compiled by the National Food and Medicine Administration Bureau.2.We used the TKRDM to treat the patient by 2-3 stage chronic renal failure and concluded the Urinary protein excretion,the serum urea nitrogen and calculated the date of renal function.3.We analysed the date by the SPSS15.0 statistics software.
Result:TKRDM and benazepril have significantly difference in proteinuria extract and urinary NAG enzyme,the serum total cholesterol was significantly distinguished by statistic means. TKRDM can improve the circulating of the blood but the benazepril doesn't have the effect.We can get a significant conclusion by statistic ways.We observed the tissue of the kidney by the way of pathohistology.We could find that the intercapillary cells and the ECM had obviously proliferation in the group of the AN.There were many foam cells in glomerulus of kidney.The cell of the renal tubule had vacuolar degeneration,analosis and cellular necrosis.There were also many protein cast and RBC cast in the nephric tubule.TKRDM group,benazepril group, TKRDM and benazepril group had different degree lessens for the index from the pathohistology. We found the group of the TKRDM and benazepril had the best conclusion by statistic way.We tested the FN,TGF-β1,MMP-9 and Col-Ⅳwhich were the compositions correlating with the fibrotic tissue by immunohistochemistry.Then we analyzed the compositions in the payhofigure by the semiquantitative analysis.TKRDM group,benazepril group,TKRDM and benazepril group could restrain the overexpression of the cytokine for the AN.In the mechanism of molecular biology,we used the ways of reverse transcription polymerase chain reaction(RT-PCR).We analyzed the cytokines which included TIMP,TGF-β1,Nephrin.All of the cytokines had a high of the date in the group of AN.The others of experimental groups had a relative lower dates.
We used the TKRDM to treat patients.Then we write down the symptoms and the renal function every month.All the symptoms,were selected from Clinical practice guide for the chronic renal disease and dialysis and Clinical practice guide to the new medicine of TCM,which correlate with the chronic renal disease.We analyzed all of the date which come from the symptoms and the renal function by spss15.0 statistic software.
Conclusion:From the dates and the analyzing of the experiments,we could get the results. First TKRDM can decrease the proteinuria and protect the function of the renal tubular for AN in rats.Second TKRDM can reduce the proliferation of ECM at different levels for AN in rats.If we use the TKRDM and benazepril,the effects of the therapeutic action will be better than use any other one of them.
For the chronic study,TKRDM can tonify spleen and kidney,benefit vital energy and smooth the blood vessel.TKRDM can also elevate the function of the entrails.The experiment hints the two points by analyzing the date of statistic results.First the TKRDM can decrease proteinuria extract and urinary NAG enzyme.Second the TKRDM can delay the aggravate speed of the renal function.
引文
1.何伟春 邢昌赢,阿霉素肾病大鼠肾皮质nephrin mRNA的表达及来氟米特对其表达的影响[J]中国中西医结合肾病杂志2007:8(1):10-13
2.Bertani T,Poggi A,Pozzoni R,et al.Adriamycin-induced nephrotic syndrome in rats[J]Laboratory Investigation,1982,46:16
3.叶任高 内科学[M]第五版 人民卫生出版社北京569
4.张路霞、王梅、王海燕等;慢性肾脏病的流行病学研究[J]中华肾脏病杂志2005,21(7);425-427
5.Remuzzi G,Bertani T.Pathophysilogy of progressive nephropathies[J]N Eng1 J Med,1998,339:1448
6.Wheeler DC,Chana RS,Topley Net al.Oxidation of lowdensity lipoprotein by mesangial cells may promoteglomerular injury[J]Kidney Int,1994;45:1628
7.Zager RA,Schimpf BM,Bredi CR.Inorganic iron effects on in vitro hypoxic proximal tubular cell injury[J].Clin Invest,1993,91:702
8.Abbate M,Zoja C,Corna D,et al.In progressive nephorpathies,overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation[J]J Am Soc Ne Phrol,1998,9(1):213
9.Ong ACM,Fine LG.Tubular-derived growth factors and cytokines in the pathogenesis of tubulointerstitial fibosis:implicationsfor human renal disease progression[J]Am J Kidney Dis,1994,23:205
10.Torbohm I,Schonermark M,Wingen A,et al.C5b-8and C5b-9moduiate the collagen release of humen glomerular epithelial cells[J]Kidney Int,1990,37:1098
11.Bosomworth MP,Aparicio SR,Hay AWM.Urine N-acetyl-b-Dglucosaminidase-a marker of tubular damage ? Nephrol Dial Transplant,1999,14:620-626.
12.Hultberg B,Ravnskov U.The excretion of N-acetyl-b-Dglucosaminidase in glomerulonephritis.Clin Nephrol,1981,15:33.
13.non-insulin-dependent diabetes mellitus Clin Nephrol,1997,48:388-389.
14.Rustom R,Castigan M,Shenkin A,et al.Proteinuria and renal tubular damage:urinary N-acetyl-b-D-glucosaminidase and isoenzymes in dissimilar renal disease.Am J Nephrol,1998,18:179-185.
15.Moorhead JF Chan MK.Lipid nephrotoxiity in chronic rogressive glom-erular and tubulointerstitial disease[J]Lancet 1982,1:1309
16.魏珉,宋红梅.持续性高脂血症对小儿肾病慢性进展的影响及治疗[J].中国实用儿科杂志,2002,17(9)
17.司晓芸,贾汝汉,黄从新等.肾小球足细胞损伤在脂质肾损害中的作用[J].广西医科大学学报,2002,19(2):157-160
18.Weisinger JR,Kempson RL,Eldridge L,et al.The nephritic syndrome:A complication of massive obesity[J]Ann Intern Med,1974,81:440-447
19.肾活检病理诊断标准指导意见 全国肾活检病理诊断研讨会[J]中华肾脏病杂志2001,17(4):270-274
20.Burton C,Harris KP.The role of proteinuria in the progression of chronic renal failure[J]AM J Kindey Dis,1996,27:765
21.Bovin BH,Tan LC.LDL stimulates mesangial fibronection production and chemo-attratant expression[J].Kidney Int 1993,43:218
22.Wheler DC,Chana RS,Topley N,et al.Oxidation of low-density lipoprotein by messangial cells may promote glomerular injury[J]Kidney Int,1994,45:1628
23.田庆印 吴葆杰 氧化型低密度脂蛋白与血栓形成[J]中国动脉硬化杂志2000,8(3):279-282
24.廖福龙.临床血液流变学[M].天津:天津科技出版社,1987:33
25.胡均培,王鸿利,董德长等.慢性肾小球疾病患者高凝状态的临床研究[J].中华肾脏病杂志.1990.6(4):357
26.金永娟.血液流变学研究方法及其进展[J].现代诊断学与治疗学杂志,1989,2(2):46
27.Kim YH,Goyal M,Kumit D et al,Foot cell with glomerular sclerosis[J],Kidney Int,2000;58(2):674
28.刘航 国外医学泌尿系统分册 足细胞表面标志及尿中足细胞的检测[J]2003;23(4):452-456
29.Klahr S.Morrissey JJ.The role of vasoactive compounds growth factors and cytolkines progression of renal disease[J].Kidney Int suppl 2000,57(suppl):7-14
30.CouchmanJR,Beavan LA,Mc Carthy KJ.Glomerular matrix synthesis,turnover and role in mesangial expansion[J].Kidney Int,1994,45(3):328-332
31.Knowlden J,Martin J,Davies M,et al.Metalloproteinases generation byhuman glomerular epithelial cell[J].Kidney Int,1995,47(4):1682-1960
32.Parsons SL,Watson SA.Matrix metalloproteinases[J].Br J Surg,1997,84(2):160
33.温继兰 李荣山 基质金属蛋白酶-9与肾脏疾病[J]国际移植与血液净化杂志2007:5(1):36-38
34.Lelongt B,Bengatta S,Delauche M,et al.Matrix metalloproteinase 9 protects mice fromanti-glomerular basementmembrane nephritisthrough its fibrinolytic activeity[J].J Exp Med,2001,193(7),793-820
35.黄帝内经素问[M]·北京:人民卫生出版社,1983:327
36.灵枢经[M]·北京:人民卫生出版社,1984:95
37.李克光主编·金匮国略讲义[M]·上海:上海科学技术出版社,1985:166
38.张介宾·景岳全书[M]·上海:上海科学技术出版社,1986:397
39.方药中主编·实用中医内科学[M]·上海:上海科学技术出版社,1985,301,458-459
40.王致谱、蔡景峰主编·中国中医药50年[M]·福建:福建科学技术出版社,1999:222
41.郑筱萸《中药新药临床研究指导原则》[M].北京:中国医药科技出版社2002年159-160,164-165
42.李中梓.医宗必读[M].人民卫生出版社,第一版,1995:364
43.陈梅芳·中西医结合防治慢性肾炎的进展[J]·中医杂志,1982,(2):73-78
44.何伟春 邢昌赢 阿霉素肾病大鼠肾皮质nephrin mRNA的表达及来氟米特对其表达的影响中国中西医结合肾病杂志2007:8(1):10-13
45.Bertani T,Poggi A,Pozzoni R,et al.Adriamycin-induced nephrotic syndrome in rats.Laboratory Investigation,1982,46:16
1.高坤 益肾清利活血治疗慢性肾炎的研究[D]南京中医药大学2005届硕士研究生论文
2.美国NKF-K/DOQI工作组 慢性肾脏病及透析的临床实践指南Ⅱ[M]王海燕 王梅主译 北京:人民卫生出版社2005年5月第一版
3.郑筱萸主编,《中药新药临床研究指导原则》[M]2002,北京:中国医药科技出版社,159-160,164-165.
4.Remuzzi G,Bertani T.Pathophysilogy of progressive nephropathies[J]N Eng1 J Med,1998,339:1448
5.高坤 孙伟教授以益肾清利活血法治疗慢性肾小球疾病的经验[J].江苏中医药,2004,25(11):19-21
6.沈淑琼,唐政.慢性肾脏疾病进展的危险因素与干预措施[J].肾脏病与透析肾移植杂志,2003,12(4):375-377
7.唐琦,史浩,王伟铭等 三种肾小球滤过率检测方法与~(99m)Tc-DTPA清除率的比较与分析[J]中华肾脏病杂志2005:21(10):589-590
8.毕增祺主编.慢性肾功能衰竭临床防治与理论基础[M],中国协和医科大学出版社,北京,2003,2-3
9.郭新峰,赖世隆,梁伟雄.中医药临床疗效评价中结局指标的选择与应用[J].广州中医药大学学报,2002,19(4):251-255
10.慢性肾衰竭的诊断、辩证分型及疗效评定(试行方案)[J]中华中医药学会肾病分会 上海中医药杂志2006,40(8):8-9
11.慢性肾脏病及透析的临床实践指南Ⅱ[M]美国NKF-K/DOQI工作组 北京 人民卫生出版社2005年5月第一版:7
12.孙伟,曾安平,严志林等.湿热病邪与慢性肾病关系探讨[J].中医研究,2000,13(1):36-37
13.何文彬.“瘀血”与“血瘀”辨[J].北京中医药大学学报,2000,23(6):14-15
14.吴兆龙 肾纤维化防治[J].中国实用内科杂志,1998,18(12):750-752.
15.桂华珍,刘启兰,张国忠“慢肾康”抗肾纤维化的实验研究[J].贵州医药,1998,22(4):250-252.
16.陈佐芳,黄志勇,王以立等.黄芪和辅酶Q_(10)对肾衰动物作用的实验研究[J].江苏医药,1989,15(1):12.
17.徐郁杰,张庆怡,吴青伟.黄芪对糖尿病大鼠早期肾肥大和蛋白尿的影响[J].上海第二医科大学学报,1997,17(5):357-359.
18.石君华,章如虹.黄芪对实验性糖尿病大鼠肾脏保护作用的实验研究[J].中国中医药科技,1999,6(5):314-316.
19.施辉,钱桐荪,蒋季杰等.补肾活血汤、黄芪治疗大鼠阿霉素肾病的研究[J].南通医学院学报,1996,16(4):503-505.
20.牟娜,张庆怡,倪兆慧等.黄芪对高糖作用下肾间质纤维细胞表达HGF的影响[J].中国中西医结合肾病杂志,2002,3(1):7
21.王亚平,李伯祥.川芎嗪防治肾间质纤维化作用的实验研究[J].中国中西医结合肾病杂志,2002,13(2):77
22.屈燧林,方勤,陈高翔等.汉防己甲素、川芎嗪和苦杏仁对人成纤维细胞的影响[J].中华肾脏病杂志,2000,16(3):186
23.林琼真,于洁,邓英辉等.丹参注射液对大鼠梗阻性肾间质纤维化的保护作用[J].中国中西医结合肾病杂志,2003,4(2):71
24.闵亚丽,俞雷,衣利黄芪当归在肾小管间质纤维化大鼠模型中的作用[J]贵阳医学院学报2003 28;(2):134
25.赵雅妮,李惊子,余凌等黄芪当归合剂对大鼠慢性肾硬化中骨桥蛋白表达的影响[J]中国中西医结合杂志200222;(8):613
26.中国药科大学.中药辞海[M].北京:中国医药科技出版社,1996.
27.沈映君 中药药理学[M]上海:上海科学技术出版社,1997
28.支广教道(日)泽泻对于水液代谢的机制[J].国外医学一中医中药分册,1997,19(5):58
29.陈敏珠.生理学报[J],1961,24(3-4):227
30.中华人民共和国药政管理局.现代实用本草[M],第1版 北京:人民卫生出版社,1997:248
31.焦红军 党参的药理作用及其临床应用[J]临床医学2005,25(4):94-95
32.肖锦松,崔风军,宁廷选.玉竹、菟丝子醇提物对烧伤小鼠免疫功能的影响[J].中国中药,1990,15(9):45-47.
33.肖锦松,崔风军,赵文仲.玉竹、菟丝子提取物对小鼠血清集落刺激因子的影响[J].中医研究,1992,5(2):12-15.
34.郭澄,张俊平,苏中武.中药菟丝子对小鼠淋转功能的影响[J].时珍国药研究,1997,8(6):515.
35.樊永平,施雪筠,黄承荣.菟丝子有效成分EOA-1对乳鼠心脏体外保存及耳后移植存活情况的影响[J].北京中医药大学学报,1996,19(6):65-66.
36.王宇翎,张艳,方明等.白花蛇舌草总黄酮的免疫调节作用[J].中国药理学通报2005,21(4):444-7
37.单保恩,张金艳,杜肖娜等.白花蛇舌草的免疫学调节活性和抗肿瘤活性[J].中国中西医结合杂志2001,21(5):370- 374
38.王桂英,李振彬,石建喜等.白花蛇舌草对吲哚美辛所致大鼠胃粘膜损伤的保护作用[J].河北中医,2001,23(1):70-71
39.徐诗伦 杜仲对垂体一肾上腺皮质功能的影响[J].中草药,1982,13(6):24
40.徐诗伦 杜仲对机体非特异性免疫功能的影响[J].中草药,1993,14(8):27
41.徐诗伦 杜仲对细胞免疫功能的影响[J].中草药,1985,11(9):15
42.朱宇红 杜仲不同炮制品增强免疫作用比较[J].中国中药杂志,1997,22(10):597
43.薛程远 杜仲叶乙醇提取物对小鼠免疫功能的影响[J].甘肃中医学院学报,1998,15(3):50
44.李献平,刘世昌 四大怀药对家蚕寿命及生长发育的影响[J]·中国中药杂志,1990;15(9):51
45.全宏勋,邹丹,张国钦等 麦饭石、牛膝对早期鸡胚发育的影响[J]·河南中医,1993;13(5):8
46.曳野宏·牛膝的药理[J]·汉方医学,1985;9(7):1(日文)
47.张志英,王绍坤,郭连魁,牛膝抗衰老的生物化学研究[J]·山西医学院学报,1995;26(1):4
48.唐藜明,吕志筠,章小萍等,牛膝多糖药效学研究[J]·中成药,1996;18(5):31
49.陈红,李祖伦·中药川、怀牛膝对小鼠肠系膜微循环的作用[J]·微循环学,1997;7(2):33
50.李学林,李威,陈国华等·牛膝活血作用的实验研究[J]·中医研究,1990;3(2):27
51.王巍,王晋桦,赵德忠等.鸡血藤、鬼箭羽和土鳖虫调脂作用的比较[J].中国中药杂志,1991,16(5):299.
52.夏卫军,程海波,张莉.鬼箭羽治疗2型糖尿病实验研究[J].陕西中医,2001,22(8):505.
53.华川,陈如泉.芪箭消瘿汤对自身免疫性甲状腺炎小鼠甲状腺超微结构的影响[J].现代中西医结合杂志,2003,12(16):1705.
54.张克锦,邹玉玲,周承明.赤土茯苓提取物对实验性鹌鹑动脉粥样硬化的预防作用[J].中草药.1991;27(9):411-412,418.
55.徐强,王蓉,徐丽华等.土茯苓对细胞兔疫和体液免疫的影响[J].中国免疫学杂志,1993;9(1):39.
56.吴丽明,张敏,土茯苓中落新妇甙的利尿和镇痛作用[J].中药材,1995;18(12):627
2.Bertani T,Poggi A,Pozzoni R,et al.Adriamycin-induced nephrotic syndrome in rats[J]Laboratory Investigation,1982,46:16
3.叶任高 内科学[M]第五版 人民卫生出版社北京569
4.张路霞、王梅、王海燕等;慢性肾脏病的流行病学研究[J]中华肾脏病杂志2005,21(7);425-427
5.Remuzzi G,Bertani T.Pathophysilogy of progressive nephropathies[J]N Eng1 J Med,1998,339:1448
6.Wheeler DC,Chana RS,Topley Net al.Oxidation of lowdensity lipoprotein by mesangial cells may promoteglomerular injury[J]Kidney Int,1994;45:1628
7.Zager RA,Schimpf BM,Bredi CR.Inorganic iron effects on in vitro hypoxic proximal tubular cell injury[J].Clin Invest,1993,91:702
8.Abbate M,Zoja C,Corna D,et al.In progressive nephorpathies,overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation[J]J Am Soc Ne Phrol,1998,9(1):213
9.Ong ACM,Fine LG.Tubular-derived growth factors and cytokines in the pathogenesis of tubulointerstitial fibosis:implicationsfor human renal disease progression[J]Am J Kidney Dis,1994,23:205
10.Torbohm I,Schonermark M,Wingen A,et al.C5b-8and C5b-9moduiate the collagen release of humen glomerular epithelial cells[J]Kidney Int,1990,37:1098
11.Bosomworth MP,Aparicio SR,Hay AWM.Urine N-acetyl-b-Dglucosaminidase-a marker of tubular damage ? Nephrol Dial Transplant,1999,14:620-626.
12.Hultberg B,Ravnskov U.The excretion of N-acetyl-b-Dglucosaminidase in glomerulonephritis.Clin Nephrol,1981,15:33.
13.non-insulin-dependent diabetes mellitus Clin Nephrol,1997,48:388-389.
14.Rustom R,Castigan M,Shenkin A,et al.Proteinuria and renal tubular damage:urinary N-acetyl-b-D-glucosaminidase and isoenzymes in dissimilar renal disease.Am J Nephrol,1998,18:179-185.
15.Moorhead JF Chan MK.Lipid nephrotoxiity in chronic rogressive glom-erular and tubulointerstitial disease[J]Lancet 1982,1:1309
16.魏珉,宋红梅.持续性高脂血症对小儿肾病慢性进展的影响及治疗[J].中国实用儿科杂志,2002,17(9)
17.司晓芸,贾汝汉,黄从新等.肾小球足细胞损伤在脂质肾损害中的作用[J].广西医科大学学报,2002,19(2):157-160
18.Weisinger JR,Kempson RL,Eldridge L,et al.The nephritic syndrome:A complication of massive obesity[J]Ann Intern Med,1974,81:440-447
19.肾活检病理诊断标准指导意见 全国肾活检病理诊断研讨会[J]中华肾脏病杂志2001,17(4):270-274
20.Burton C,Harris KP.The role of proteinuria in the progression of chronic renal failure[J]AM J Kindey Dis,1996,27:765
21.Bovin BH,Tan LC.LDL stimulates mesangial fibronection production and chemo-attratant expression[J].Kidney Int 1993,43:218
22.Wheler DC,Chana RS,Topley N,et al.Oxidation of low-density lipoprotein by messangial cells may promote glomerular injury[J]Kidney Int,1994,45:1628
23.田庆印 吴葆杰 氧化型低密度脂蛋白与血栓形成[J]中国动脉硬化杂志2000,8(3):279-282
24.廖福龙.临床血液流变学[M].天津:天津科技出版社,1987:33
25.胡均培,王鸿利,董德长等.慢性肾小球疾病患者高凝状态的临床研究[J].中华肾脏病杂志.1990.6(4):357
26.金永娟.血液流变学研究方法及其进展[J].现代诊断学与治疗学杂志,1989,2(2):46
27.Kim YH,Goyal M,Kumit D et al,Foot cell with glomerular sclerosis[J],Kidney Int,2000;58(2):674
28.刘航 国外医学泌尿系统分册 足细胞表面标志及尿中足细胞的检测[J]2003;23(4):452-456
29.Klahr S.Morrissey JJ.The role of vasoactive compounds growth factors and cytolkines progression of renal disease[J].Kidney Int suppl 2000,57(suppl):7-14
30.CouchmanJR,Beavan LA,Mc Carthy KJ.Glomerular matrix synthesis,turnover and role in mesangial expansion[J].Kidney Int,1994,45(3):328-332
31.Knowlden J,Martin J,Davies M,et al.Metalloproteinases generation byhuman glomerular epithelial cell[J].Kidney Int,1995,47(4):1682-1960
32.Parsons SL,Watson SA.Matrix metalloproteinases[J].Br J Surg,1997,84(2):160
33.温继兰 李荣山 基质金属蛋白酶-9与肾脏疾病[J]国际移植与血液净化杂志2007:5(1):36-38
34.Lelongt B,Bengatta S,Delauche M,et al.Matrix metalloproteinase 9 protects mice fromanti-glomerular basementmembrane nephritisthrough its fibrinolytic activeity[J].J Exp Med,2001,193(7),793-820
35.黄帝内经素问[M]·北京:人民卫生出版社,1983:327
36.灵枢经[M]·北京:人民卫生出版社,1984:95
37.李克光主编·金匮国略讲义[M]·上海:上海科学技术出版社,1985:166
38.张介宾·景岳全书[M]·上海:上海科学技术出版社,1986:397
39.方药中主编·实用中医内科学[M]·上海:上海科学技术出版社,1985,301,458-459
40.王致谱、蔡景峰主编·中国中医药50年[M]·福建:福建科学技术出版社,1999:222
41.郑筱萸《中药新药临床研究指导原则》[M].北京:中国医药科技出版社2002年159-160,164-165
42.李中梓.医宗必读[M].人民卫生出版社,第一版,1995:364
43.陈梅芳·中西医结合防治慢性肾炎的进展[J]·中医杂志,1982,(2):73-78
44.何伟春 邢昌赢 阿霉素肾病大鼠肾皮质nephrin mRNA的表达及来氟米特对其表达的影响中国中西医结合肾病杂志2007:8(1):10-13
45.Bertani T,Poggi A,Pozzoni R,et al.Adriamycin-induced nephrotic syndrome in rats.Laboratory Investigation,1982,46:16
1.高坤 益肾清利活血治疗慢性肾炎的研究[D]南京中医药大学2005届硕士研究生论文
2.美国NKF-K/DOQI工作组 慢性肾脏病及透析的临床实践指南Ⅱ[M]王海燕 王梅主译 北京:人民卫生出版社2005年5月第一版
3.郑筱萸主编,《中药新药临床研究指导原则》[M]2002,北京:中国医药科技出版社,159-160,164-165.
4.Remuzzi G,Bertani T.Pathophysilogy of progressive nephropathies[J]N Eng1 J Med,1998,339:1448
5.高坤 孙伟教授以益肾清利活血法治疗慢性肾小球疾病的经验[J].江苏中医药,2004,25(11):19-21
6.沈淑琼,唐政.慢性肾脏疾病进展的危险因素与干预措施[J].肾脏病与透析肾移植杂志,2003,12(4):375-377
7.唐琦,史浩,王伟铭等 三种肾小球滤过率检测方法与~(99m)Tc-DTPA清除率的比较与分析[J]中华肾脏病杂志2005:21(10):589-590
8.毕增祺主编.慢性肾功能衰竭临床防治与理论基础[M],中国协和医科大学出版社,北京,2003,2-3
9.郭新峰,赖世隆,梁伟雄.中医药临床疗效评价中结局指标的选择与应用[J].广州中医药大学学报,2002,19(4):251-255
10.慢性肾衰竭的诊断、辩证分型及疗效评定(试行方案)[J]中华中医药学会肾病分会 上海中医药杂志2006,40(8):8-9
11.慢性肾脏病及透析的临床实践指南Ⅱ[M]美国NKF-K/DOQI工作组 北京 人民卫生出版社2005年5月第一版:7
12.孙伟,曾安平,严志林等.湿热病邪与慢性肾病关系探讨[J].中医研究,2000,13(1):36-37
13.何文彬.“瘀血”与“血瘀”辨[J].北京中医药大学学报,2000,23(6):14-15
14.吴兆龙 肾纤维化防治[J].中国实用内科杂志,1998,18(12):750-752.
15.桂华珍,刘启兰,张国忠“慢肾康”抗肾纤维化的实验研究[J].贵州医药,1998,22(4):250-252.
16.陈佐芳,黄志勇,王以立等.黄芪和辅酶Q_(10)对肾衰动物作用的实验研究[J].江苏医药,1989,15(1):12.
17.徐郁杰,张庆怡,吴青伟.黄芪对糖尿病大鼠早期肾肥大和蛋白尿的影响[J].上海第二医科大学学报,1997,17(5):357-359.
18.石君华,章如虹.黄芪对实验性糖尿病大鼠肾脏保护作用的实验研究[J].中国中医药科技,1999,6(5):314-316.
19.施辉,钱桐荪,蒋季杰等.补肾活血汤、黄芪治疗大鼠阿霉素肾病的研究[J].南通医学院学报,1996,16(4):503-505.
20.牟娜,张庆怡,倪兆慧等.黄芪对高糖作用下肾间质纤维细胞表达HGF的影响[J].中国中西医结合肾病杂志,2002,3(1):7
21.王亚平,李伯祥.川芎嗪防治肾间质纤维化作用的实验研究[J].中国中西医结合肾病杂志,2002,13(2):77
22.屈燧林,方勤,陈高翔等.汉防己甲素、川芎嗪和苦杏仁对人成纤维细胞的影响[J].中华肾脏病杂志,2000,16(3):186
23.林琼真,于洁,邓英辉等.丹参注射液对大鼠梗阻性肾间质纤维化的保护作用[J].中国中西医结合肾病杂志,2003,4(2):71
24.闵亚丽,俞雷,衣利黄芪当归在肾小管间质纤维化大鼠模型中的作用[J]贵阳医学院学报2003 28;(2):134
25.赵雅妮,李惊子,余凌等黄芪当归合剂对大鼠慢性肾硬化中骨桥蛋白表达的影响[J]中国中西医结合杂志200222;(8):613
26.中国药科大学.中药辞海[M].北京:中国医药科技出版社,1996.
27.沈映君 中药药理学[M]上海:上海科学技术出版社,1997
28.支广教道(日)泽泻对于水液代谢的机制[J].国外医学一中医中药分册,1997,19(5):58
29.陈敏珠.生理学报[J],1961,24(3-4):227
30.中华人民共和国药政管理局.现代实用本草[M],第1版 北京:人民卫生出版社,1997:248
31.焦红军 党参的药理作用及其临床应用[J]临床医学2005,25(4):94-95
32.肖锦松,崔风军,宁廷选.玉竹、菟丝子醇提物对烧伤小鼠免疫功能的影响[J].中国中药,1990,15(9):45-47.
33.肖锦松,崔风军,赵文仲.玉竹、菟丝子提取物对小鼠血清集落刺激因子的影响[J].中医研究,1992,5(2):12-15.
34.郭澄,张俊平,苏中武.中药菟丝子对小鼠淋转功能的影响[J].时珍国药研究,1997,8(6):515.
35.樊永平,施雪筠,黄承荣.菟丝子有效成分EOA-1对乳鼠心脏体外保存及耳后移植存活情况的影响[J].北京中医药大学学报,1996,19(6):65-66.
36.王宇翎,张艳,方明等.白花蛇舌草总黄酮的免疫调节作用[J].中国药理学通报2005,21(4):444-7
37.单保恩,张金艳,杜肖娜等.白花蛇舌草的免疫学调节活性和抗肿瘤活性[J].中国中西医结合杂志2001,21(5):370- 374
38.王桂英,李振彬,石建喜等.白花蛇舌草对吲哚美辛所致大鼠胃粘膜损伤的保护作用[J].河北中医,2001,23(1):70-71
39.徐诗伦 杜仲对垂体一肾上腺皮质功能的影响[J].中草药,1982,13(6):24
40.徐诗伦 杜仲对机体非特异性免疫功能的影响[J].中草药,1993,14(8):27
41.徐诗伦 杜仲对细胞免疫功能的影响[J].中草药,1985,11(9):15
42.朱宇红 杜仲不同炮制品增强免疫作用比较[J].中国中药杂志,1997,22(10):597
43.薛程远 杜仲叶乙醇提取物对小鼠免疫功能的影响[J].甘肃中医学院学报,1998,15(3):50
44.李献平,刘世昌 四大怀药对家蚕寿命及生长发育的影响[J]·中国中药杂志,1990;15(9):51
45.全宏勋,邹丹,张国钦等 麦饭石、牛膝对早期鸡胚发育的影响[J]·河南中医,1993;13(5):8
46.曳野宏·牛膝的药理[J]·汉方医学,1985;9(7):1(日文)
47.张志英,王绍坤,郭连魁,牛膝抗衰老的生物化学研究[J]·山西医学院学报,1995;26(1):4
48.唐藜明,吕志筠,章小萍等,牛膝多糖药效学研究[J]·中成药,1996;18(5):31
49.陈红,李祖伦·中药川、怀牛膝对小鼠肠系膜微循环的作用[J]·微循环学,1997;7(2):33
50.李学林,李威,陈国华等·牛膝活血作用的实验研究[J]·中医研究,1990;3(2):27
51.王巍,王晋桦,赵德忠等.鸡血藤、鬼箭羽和土鳖虫调脂作用的比较[J].中国中药杂志,1991,16(5):299.
52.夏卫军,程海波,张莉.鬼箭羽治疗2型糖尿病实验研究[J].陕西中医,2001,22(8):505.
53.华川,陈如泉.芪箭消瘿汤对自身免疫性甲状腺炎小鼠甲状腺超微结构的影响[J].现代中西医结合杂志,2003,12(16):1705.
54.张克锦,邹玉玲,周承明.赤土茯苓提取物对实验性鹌鹑动脉粥样硬化的预防作用[J].中草药.1991;27(9):411-412,418.
55.徐强,王蓉,徐丽华等.土茯苓对细胞兔疫和体液免疫的影响[J].中国免疫学杂志,1993;9(1):39.
56.吴丽明,张敏,土茯苓中落新妇甙的利尿和镇痛作用[J].中药材,1995;18(12):627